Global Primary Biliary Cholangitis Market Analysis

back-icon

Back to Report

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Free Sample Report Free Sample Report Inquire Before Buying Inquire Before Buy Now Buy Now

Global Primary Biliary Cholangitis Market Analysis

  • Pharmaceutical
  • Jan 2025
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Die primäre biliäre Zirrhose ist eine chronische Lebererkrankung, die Entzündungen, Fibrose und Gallengangsobstruktionen verursacht und zum Verlust der kleinen Gallengänge in der Leber führt. Autoimmunität, Infektionen und/oder genetische Veranlagung sind mögliche Ursachen für eine primäre biliäre Zirrhose. Juckreiz, Osteoporose, hoher Cholesterinspiegel und Malabsorption von Fett und fettlöslichen Vitaminen sind Symptome einer primären biliären Zirrhose, die zu einer Hepatomegalie, Hyperpigmentierung, Splenomegalie, Gelbsucht, Sicca-Syndrom oder Kayser-Fleischer-Ringen führen kann. Eine primäre biliäre Zirrhose entwickelt sich im Laufe der Zeit und kann schließlich zum vollständigen Leberversagen führen.

Filled Map Analysis

Frequently Asked Questions

The market is segmented based on Segmentation, By Diagnosis (Imaging Tests, Blood Tests, Others), Treatment Type (Liver Transplantation, Drug Therapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2032 .
The Global Primary Biliary Cholangitis Market size was valued at USD 1.05 USD Billion in 2024.
The Global Primary Biliary Cholangitis Market is projected to grow at a CAGR of 10.5% during the forecast period of 2025 to 2032.
The major players operating in the market include F. Hoffmann-La Roche Ltd. , Mylan N.V. , Teva Pharmaceutical Industries Ltd. , Sanofi , Pfizer Inc. , GlaxoSmithKline plc , Novartis AG , Merck &amp, Co.Inc. , Allergan , AstraZeneca , Johnson &amp, Johnson Private Limited , Hikma Pharmaceuticals PLC , Bristol-Myers Squibb Company , Bayer AG , Boehringer Ingelheim International GmbH. , Dr. Reddy&rsquo,s Laboratories Ltd. , Gilead SciencesInc. , Amgen Inc. , Eli Lilly and Company , AbbVie Inc. , Lupin , Allergan .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.